850655-62-8Relevant articles and documents
A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia
Sellmer, Andreas,Pilsl, Bernadette,Beyer, Mandy,Pongratz, Herwig,Wirth, Lukas,Elz, Sigurd,Dove, Stefan,Henninger, Sven Julian,Spiekermann, Karsten,Polzer, Harald,Klaeger, Susan,Kuster, Bernhard,B?hmer, Frank D.,Fiebig, Heinz-Herbert,Kr?mer, Oliver H.,Mahboobi, Siavosh
supporting information, (2020/03/24)
Mutants of the FLT3 receptor tyrosine kinase (RTK) with duplications in the juxtamembrane domain (FLT3-ITD) act as drivers of acute myeloid leukemia (AML). Potent tyrosine kinase inhibitors (TKi) of FLT3-ITD entered clinical trials and showed a promising,
METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
-
Paragraph 0828; 0829, (2017/09/06)
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
ISOINDOLINE DERIVATIVES
-
Page/Page column 46, (2016/05/02)
The present invention relates to isoindoline derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.
